{
    "Clinical Trial ID": "NCT00537771",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arimidex Group",
        "  Anastrozole(ARIMIDEX): 1 mg once daily oral dose",
        "INTERVENTION 2: ",
        "  TAM Group",
        "  Tamoxifen : 20 mg once daily oral dose"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically proven HR+ invasive breast cancer",
        "  Completed all primary surgery and chemotherapy (if given), and were candidates to receive hormonal adjuvant therapy",
        "  Postmenopausal woman",
        "Exclusion Criteria:",
        "  clinical evidence of metastatic disease",
        "  previous adjuvant hormonal therapy for breast cancer",
        "liver diseases"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Incidence of Fatty Liver Disease",
        "  The primary objective is to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidence of fatty liver diseases.",
        "  Time frame: At 48 weeks, 96 weeks, 144 weeks",
        "Results 1: ",
        "  Arm/Group Title: Arimidex Group",
        "  Arm/Group Description: Anastrozole(ARIMIDEX): 1 mg once daily oral dose",
        "  Overall Number of Participants Analyzed: 178",
        "  Measure Type: Number",
        "  Unit of Measure: participants  48 weeks: 9",
        "  96 weeks: 15",
        "144 weeks: 26",
        "Results 2: ",
        "  Arm/Group Title: TAM Group",
        "  Arm/Group Description: Tamoxifen : 20 mg once daily oral dose",
        "  Overall Number of Participants Analyzed: 175",
        "  Measure Type: Number",
        "  Unit of Measure: participants  48 weeks: 53",
        "  96 weeks: 66",
        "144 weeks: 72"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 4/178 (2.25%)",
        "  Cardiac failure 1/178 (0.56%)",
        "  Supraventricular extrasystoles 0/178 (0.00%)",
        "  Hepatic cyst 1/178 (0.56%)",
        "  Cervicitis 0/178 (0.00%)",
        "  Fall 1/178 (0.56%)",
        "  Joint dislocation 1/178 (0.56%)",
        "  Spinal fracture 1/178 (0.56%)",
        "  Cyst 0/178 (0.00%)",
        "  Uterine atony 0/178 (0.00%)",
        "Adverse Events 2:",
        "  Total: 4/175 (2.29%)",
        "  Cardiac failure 0/175 (0.00%)",
        "  Supraventricular extrasystoles 1/175 (0.57%)",
        "  Hepatic cyst 0/175 (0.00%)",
        "  Cervicitis 2/175 (1.14%)",
        "  Fall 0/175 (0.00%)",
        "  Joint dislocation 0/175 (0.00%)",
        "  Spinal fracture 0/175 (0.00%)",
        "  Cyst 1/175 (0.57%)",
        "  Uterine atony 1/175 (0.57%)"
    ]
}